Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic Plc's (NYSE: MDT) Q1 FY22 sales of $7.9 billion increased 23% Y/Y as reported and 19% on an organic basis, beating the consensus estimate of $7.86 billion. Q1 adjusted EPS of $1.41 more than doubled from $0.62 a year ago, surpassing the analyst consensus of $1.32.

Medtronic Q1 Earnings Double As Elective Procedures Recover

Shares of Medtronic (NYSE:MDT) moved higher by 0.3% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 127.42% over the past year to $1.41, which beat the estimate of $1.32.

Medtronic: Q1 Earnings Insights

Shares of Medtronic PLC MDT, -1.09% tacked on 0.6% in premarket trading Tuesday, after the medical device maker reported fiscal first-quarter profit and sales that beat expectations, and nudged up its full-year earnings outlook, citing a strong recovery from the impact of the COVID-19 pandemic on elective procedures. Net income for the quarter to July 30 rose to $763 million, or 56 cents a share, from $487 million, or 36 cents a share, in the year-ago period.

Medtronic stock gains after profit and sales beats, outlook for earnings nudged up

DUBLIN, Aug. 24, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights Revenue of $8.0 Billion Increased 23% Reported and 19% Organic GAAP Diluted EPS of $0.56; Non-GAAP Diluted EPS of $1.41 Company Reiterates FY22 Revenue Guidance; Raises Lower End of FY22 EPS Guidance by 5 cents "FY22 is off to a strong start - Q1 reflects solid execution & continued procedure recovery" Chairman & CEO Geoff Martha  The company reported first quarter worldwide revenue of $7.987 billion, an increase of 23% as reported and 19% on an organic basis, which excludes the $245 million benefit of foreign currency translation.

Medtronic Reports First Quarter Fiscal 2022 Financial Results

Medtronic (MDT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Medtronic (MDT) This Earnings Season?

Medtronic is one of the world's leading medical technology companies, posting more than $30 billion in revenue in fiscal year 2021.

Why Medtronic Is A Med-Tech Powerhouse Worth Buying

DUBLIN, Aug. 23, 2021 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Friday, August 20, 2021, approved the fiscal year 2022 second quarter cash dividend of $0.63 per ordinary share, representing a 9 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2021.

Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2022

Best Buy

Palo Alto Networks

New Oriental Education & Technology Group

Pinduoduo Inc - ADR

After U.S. markets closed Thursday and before they opened Friday, semiconductor equipment maker Applied Materials and farming and heavy equipment maker Deere, respectively, reported quarterly earnings.

Earnings Previews: Best Buy, Palo Alto Networks and More

Robust performances of Micra leadless pacemaker, Cobalt, and Crome High Power devices are likely to have boosted Medtronic's (MDT) CRM business in Q1.

Medtronic (MDT) Q1 Earnings to Benefit From Market Share Gains

Medtronic's (MDT) acquisition of Intersect ENT is intended to offer a wide-ranging variety of solutions to help surgeons treat CRS patients.

Medtronic (MDT) to Expand Neuroscience Line With XENT Buyout

DUBLIN, Aug. 10, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) announced today that it will report financial results for its first quarter of fiscal year 2022 on Tuesday, August 24, 2021. A news release will be issued at approximately 5:45 a.m.

Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2022

Intersect ENT

NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed acquisition of the company by Medtronic plc (NYSE: MDT). Stockholders will receive $28.25 for each share of Intersect ENT stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.

Medtronic is a Dividend Champion with 44 consecutive years of dividend growth. Shares currently offer a yield of 1.96%. Medtronic is a leader in the medtech space with ample cash to spend on R&D and tuck-in M&A.

Medtronic: A Fully Valued Dividend Champion

AbbVie

Abbott Labs

Anthem

Bristol-Myers

Cigna

Johnson & Johnson

Merck

PIMCO Corporate & Income Opportunity Fund

Cohen & Steers Reit And Preferred Income Fund Inc

abrdn Life Sciences Investors 

Thermo Fisher Scientific

UnitedHealth Group

A monthly income stream provides a lot of flexibility for the income investor. Monthly dividends makes DCA work even better.

3 Big Dividends, Paying Monthly, For Your Retirement Basea

Medtronic plc (NYSE:MDT) announced it entered into a definitive agreement with Intersect ENT (NASDAQ: XENT) for $1.1 billion.  The post Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion appeared first on Pulse 2.0.

Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion

NEW YORK, Aug. 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intersect ENT, Inc. ("Intersect" or the "Company") (NASDAQ: XENT) in connection with the proposed acquisition of the Company by Medtronic plc ("Medtronic") (NYSE:MDT).  Under the terms of the merger agreement, the Company's shareholders will receive $28.25 per share in cash for each share of Intersect common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.

Medtronic plc (NYSE:MDT) has agreed to acquire Intersect ENT Inc (NASDAQ:XENT) for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion.  Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures.

Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share

DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic will acquire all outstanding shares of Intersect ENT for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion.

Medtronic to Acquire Intersect ENT

Apple

Blackrock Inc

Disney

Global X SuperDividend US ETF

Amplify CWP Dividend & Option Income ETF

Cohen & Steers Closed-End Opportunity Fund

Corning

Home Depot

Xtrackers USD High Yield Corporate Bond ETF

iShares International Select Dividend ETF

JPMorgan Chase & Co

Mastercard

Global X MLP ETF

Altria

Microsoft

NIKE

Realty Income Corp

Global X U.S. Preferred ETF

Invesco NASDAQ Next Gen 100 ETF

Invesco Nasdaq 100 ETF

iShares Mortgage Real Estate ETF

Starbucks

My Dividend Growth Portfolio July Update: $500K Across 32 Holdings, 3 Buys, And 2 Sells

News for Medtronic Stock (MDT)